Funding SupportThe private placement with Nantahala Capital, Rosalind Advisors, and CEO Vince Angotti provides Talphera with significant funding, supporting its initiatives and potentially strengthening its financial position.
Study AccelerationTalphera reached an agreement with the FDA to reduce the number of patients for the Phase 3 NEPHRO CRRT study to 70 patients, from 166, which should allow the trial to complete faster and reduce potential total cash expenses.